Aesthetics Biomedical represents a team of the best and the brightest innovators in the global aesthetics market who have created programs that are designed to create optimal results for the consumer. ABM is a thought leader in the innovation of treatment serums, masks, numbing cream and recovery agents to optimize the results of the treatments we design.
Aesthetics Biomedical coined the phrase The Vivace Experience™, to reflect our vision to not only provide a single device—The Vivace—or a product, but to deliver a comprehensive and integrated experience that maximizes the outcome for the patient. It is this advantage we bring to our clients, physicians and consumers alike. We never rest until we know we’re bringing excellence to the market. We integrate state-of-the-art education and training to guarantee the best possible outcomes for our clients and their patients for the lifetime of the relationship.
Cypris Medical is a medical device company committed to developing and commercializing minimally invasive treatments in plastic surgery. Our proprietary technology is an innovative system designed to simplify suturing in difficult to reach locations. Cypris leverages over 40 years of cross-functional experience in the medical device and pharmaceutical industry in conjunction with a vast network of experts to get products from concept to launch quickly.
Cytrellis Biosystems, Inc. is a clinical stage medical technology company developing a new, proprietary class of aesthetic devices. Our devices are designed to remove sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners an unprecedented ability to improve age related changes in skin and restore youthful beauty. Cytrellis is dedicated to working with leading physicians and partners to develop unique product solutions which emphasize safety, clinical results and improved quality of life. We are a Boston-based venture capital backed company.
Recros Medica was co-founded in 2014 by Dr. Edward Knowlton, the board-certified plastic surgeon who invented and founded Thermage. Dr. Knowlton's newest invention, Rotational Fractional Resection, is a platform technology for use by Dermatologists, Plastic Surgeons and other aesthetic physicians that treat skin laxity and focal aesthetic contour deformities. Recros Medica is the winner of the 2017 OCTANe Launchpad award as the most compelling medical device startup in S. California.
Sinclair has a portfolio of differentiated, complementary aesthetics technologies with a focus on collagen stimulation. Our products are experiencing significant growth as we target clinical demand for effective, high quality, longer duration, natural looking and minimally invasive treatments.
Zift Medical is developing technology intended to shift cosmetic procedure patients from a highly invasive operation under general anesthesia in an operating room to a minimally invasive procedure using local anesthetic in a clinic setting.
This minimally invasive procedure, called a ZiftLift™, uses a platform technology to secure soft tissue to bone. Cosmetic procedures such as forehead or brow lifts are the first target market. With this technology, patients see immediate effects with minimal discomfort and fast recovery time.
Reducing the barriers to cosmetic procedures, such as invasiveness, discomfort and long recovery times, increases the potential patient population. Moving to a clinic setting expands the provider base to include multiple specialties such as Dermatologists, Plastic, Facial Plastic and Oculoplastic Surgeons.
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial products and therapeutic pipeline.
Obalon Therapeutics is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
Founded in 2014, PatientPop was conceived with one simple goal in mind: Help practices grow automatically.
We understand the challenges doctors face simply focusing on patient care and running their practice. Many practices don’t have the dedicated resources, tools, and time it takes to build a comprehensive marketing solution to help grow their business.
PatientPop is the first growth-focused marketing platform that accelerates new patient growth by automating practice marketing and eliminating the need for dedicated marketing resources.
R2 Dermatology was founded in late 2014 upon the licensing of technology created by scientists R. Rox Anderson, MD, Director of the Wellman Center of Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School; Dieter Manstein, MD, PhD, of the Cutaneous Biology Research Center in the Department of Dermatology at Massachusetts General Hospital; and Henry H.L. Chan, MD, PhD, Honorary Clinical Professor, Department of Medicine, The University of Hong Kong and the Visiting Scientist of the Wellman Center for Photomedicine, Massachusetts General Hospital.
Red Spot Interactive
Since 2010, Red Spot has provided its Integrated Marketing and Patient Acquisition Platform to over 150 medical practices across the country. Red Spot maximizes profits from marketing and patient acquisition, while reducing time requirements and operating costs associated with running the business.
Red Spot Interactive was founded on the principle that doctors should be able to grow their businesses profitably by understanding their return on investment down to the penny across the entire patient acquisition spectrum. Technology, creative and professional services, along with domain knowledge traditionally only afforded to Fortune 500 companies should be readily available to practices at an affordable price and provide them a strategic advantage against their competition. In addition, these advancements in technology should bring scale and transparency to the key performance indicators of the practice and patient acquisition spectrum.
SOLTÉGO is an early stage specialty biopharmaceutical and aesthetic innovator advancing the science of skin darkening, sun prevention, and anti-aging by harnessing the body’s own healing power and delivering proven biological activity.
Based on their disruptive technology, the founders created SOLTÉGO in late 2017. SOLTÉGO is an emerging player in two distinct areas: Pharmaceutical for several therapeutic indications, including certain forms of Albinism and Vitiligo and Physician Dispensed Skincare. The breakthrough proprietary and innovative technology is based on the science of salt-inducible kinase inhibitors (SIK inhibitors), designed to help protect the skin against UV induced photo-damage and aging skin. This technology will create a new class of products in Physician Dispensed Skincare. The activation of the tanning/pigmentation pathway by this new class of small molecules is physiologically identical to UV-induced pigmentation (darkening) without the DNA-damaging effects of UV. In the case of Albinism and Vitiligo, in certain patient populations, these novel compounds may improve the ability of resident skin melanocytes to produce dark pigment restore the normal look and function.
SOLTÉGO’s unique patented technology triggers melanin production to darken and protect the skin against UV-induced skin damage and cancer formation, SOLTÉGO owns a library of ingredients, which have been proven in pharmacology models to be safe and highly effective.